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Cell Death Mediators in Autoimmune Minireview
DiabetesÐNo Shortage of Suspects
Christophe Benoist and Diane Mathis the defining characteristic of autoimmune diabetes, we
are still rather ignorant about the events immediatelyInstitut de GeÂ neÂ tique et de Biologie MoleÂculaire
preceding and directly responsible for b cell death. It iset Cellulaire
known that the process ultimately depends on T cells,(CNRS/INSERM/ULP)
but it is not at all clear whether they promote destruction1 rue Laurent Fries
primarily by direct or indirect means. Two general mech-67404 Illkirch
anisms have been proposed,as reviewed by Bach (1994)C. U. de Strasbourg
and Tisch and McDevitt (1996) and illustrated in FigureFrance
1. The first (recognition-linked) attributes the specificity
of destruction to cytotoxic T cell recognition of autoanti-
gens displayed by major histocompatibility complex
A hallmark of many organ-specific autoimmune dis- (MHC) molecules on b cells. Thus killing is provoked by
eases is an exquisitely specific destruction of one of direct recognition of a target on the b cell, and necessi-
the cell types that makes up the organ. Over the years, tates T cell±b cell contact. In mice, this would imply
much interest has been focused on the initiator phase recognition of class I±restricted antigens by CD81 cells
of such disorders, exploring the factors that permit or because b cells appear not to express MHC class II
provoke the autoimmune attack, and devising means to molecules. Evidence consistent with such a mechanism
interfere with them. More recently, no doubt a reflection comes from a variety of observations: that CD81 cells
of the impressive advances in the cell death field (re- follow CD41 cells into the islets when splenocytes from
viewed in Vaux and Strasser, 1996), greater attention diabetic donors are transferred to healthy recipients;
has been paid to the effector phase, the goal being to that both CD41 and CD81 T cells are required to transfer
delineate the mechanism(s) by which the autoimmune diabetes even though the former, alone, can invade host
attackers promote death of the target cells. So far, this islets; that certain CD81 clones isolated from diabetic
has not proven a simple task. mice provoke diabetes upon transfer into T cell±
Studies on insulin-dependent diabetes mellitus can deficient hosts; that diabetes but not insulitis is reduced
when adult (insulitic) NOD mice are injected with anti-be taken as an example (for reviews, see Bach, 1994;
MHC class I or anti-CD8 monoclonal antibodies (MAbs);Tisch and McDevitt, 1996).This disorder is characterized
and that CD81 T cells from diabetic animals can specifi-by specific destruction of the insulin-producing b cells
cally attach to and lyse b cells in vitro. It might also beof the islets of Langerhans of the pancreas, resulting
worth mentioning that CD81 T cells often, though notin insufficient insulin production, eventually leading to
always, dominate islet infiltrates in diabetes patients.hyperglycemia. Much of what we know (or at least sus-
However, there exists evidence against this scenario,pect) about the etiology and pathogenesis of autoim-
notably that some CD41 T cell clones can provoke dia-mune diabetes comes from studies on small animal
betes in the absence of CD81 cells in transfer ormodelsÐin particular the nonobese diabetic (NOD)
transgenic systems. In addition, it was recently reportedmouse, which spontaneously develops a disease with
that splenocytes from diabetic donors can transfer dis-many of the features of the human disorder. There has
ease into hosts lacking MHC class I molecules.emerged a complex picture of pathogenesis in the NOD
The second proposed mechanism for islet b cell de-mouse, involving distinct phases and multiple lympho-
struction (activation-linked) is an indirect one, whereincyte populations. It has been suggested that disease
just the proximity of b cells to angry T cells leads toprogression is regulated at two checkpoints (reviewed
their death. It stemmed from a pair of perplexing obser-in AndreÂ et al., 1996): first, no signs of pathology are
vations: CD41 T cellscan promote diabetes in NOD miceevident until 3±5 weeks of age, when leukocyte infiltra-
in theabsence of CD81 cells, yet MHC class II molecules
tion of the islets (or insulitis) begins; second, the islet
do not appear to be expressed on b cells. Thus, it has
infiltrates remain rather harmless until about 12±15
been proposed that potentially pathogenic CD41 cells
weeks of age, when active destruction of the b cells are stimulated by recognition of autoantigens encoun-
(culminating in diabetes) ensues. It is known that T lym- tered on more typical antigen-presenting cells (APCs)
phocytes are critical throughout the unfolding of dis- within the islets, such as macrophages and dendritic
ease, but the role of particular subsets has been rather cells (pancreatic autoantigens being shed from b cells,
controversial. A consensus seems to be emerging that if part of the secretory machinery, or picked up from
CD81 T cells somehow initiate the process, CD41 T damaged or phagocytized b cells, perhaps following
cells are the predominant islet invaders during the early primary CD8-mediated cytotoxicity); as a result of such
stages, and both CD41 and CD81 cells are required for T±APC interactions, the actived T cell may directly kill
the maximum destruction of b cells (discussed at length the bystander b cell (for example, through Fas/FasL
in Wang et al., 1996). To aid in elucidating the roles of interaction) ([a] in Figure 1), may produce soluble media-
the different subsets, several groups have developed tors that induce b cell death (b), or may activate the
transfer or T cell receptor (TCR) transgenic (tg) models cytocidal functions of macrophages (c). The nature of
that focus on a particular CD41 or CD81 T cell specificity critical soluble mediator(s) is controversial: interferon
directed at either a natural or artificial diabetogenic an- (IFNg), interleukin (IL)-1, tumor necrosis factor a (TNFa),
tigen. IL-6, and nitric oxide have all been implicated. An addi-
tional complexity is that some of these molecules haveAlthough the destruction of pancreatic islet b cells is
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Figure 1. Two Proposed Mechanisms for Is-
let b Cell Destruction in Autoimmune Dia-
betes
potent synergistic effects when in combination, and that by transfer experiments infusing polyclonal populations
of effector T cells from diabetic NOD mice into irradiatedcertain of them are active, sometimes differentially, as
either membrane or soluble forms. Also debated is at NOD versus NOD lpr/lpr recipients.
The possibility that distinct mechanisms of b cellwhat point the b cells, themselves, enter the process
ultimately leading to destruction: i.e., are they induced death might reign in the different diabetes models is
underlined by recent observations made by otherto synthesize certain of these mediators, hastening their
own death? Interestingly, it has been reported that in groups. Zinkernagel, Hengartner, and colleagues have
studied a model of autoimmune diabetes based on avitro incubation of islets with certain cytokines leads to
destruction of b cells preferentially, providing a potential transgenic mouse line that expresses the glycoprotein
of lymphocytic choriomeningitis virus (LCMV) specifi-explanation for the b cell specificity of killing during
diabetes, although this has been disputed. At present, cally in islet b cells (Ohashi et al., 1991). These mice are
free of pathogenesis until infected with LCMV, whenwe are far from being able to draw a coherent picture
of the events immediately preceding b cell death during they develop rampant insulitis and diabetes. By crossing
in a null mutation of the perforin gene, this group demon-autoimmune attack. It will probably turn out that they
can die by multiple means during the development of strated that their diabetes model is dependent on per-
forin-mediated cytotoxicity (KaÈ gi et al., 1996), consistentdiabetes and this could evolve through the course of
disease. with the fact that CD81 T cells are known to be the
primary effector cells. Evidence that perforin was actu-This issueof Cell bringsnew informationonthis impor-
tant matter. Chervonsky et al. (1997 [this issue of Cell]) ally playing its role at the stage of b cell destruction
was two-fold: (1) that only diabetes, not insulitis, wasreport experiments suggesting a role for Fas/Fas ligand
(FasL) interactions in b cell death in at least one form affected; and (2) that activated T cells from a TCR tg
mouse line expressing an LCMV glycoprotein-specificof autoimmune diabetes. Three points are most relevant.
First, NOD lpr/lpr mice, deficient in Fas expression be- TCR and also carrying the perforin mutation could trans-
fer insulitis but not diabetes into wild-type recipients,cause of an incapacitating mutation in the fas gene did
not develop spontaneous diabetes. Second, transfer of while cells from TCR tg littermates not bearing the muta-
tion transferred both. Katz and colleagues have argueda particular NOD-derived, islet-reactive CD81 T cell
clone (Wong et al., 1996) into young, irradiated NOD for the importance of still another mediator of b cell
death on the basis of results with a third diabetes modelanimals led to diabetes several days later, but a parallel
transfer into NOD lpr/lpr recipients, did not provoke dis- (Pakala et al., 1997). These experiments consisted of
grafting islets from wild-type or various mutant miceease. Transfer into animals engineered to express FasL
constitutively on islet b cells promoted diabetes unusu- into animals previously treated with streptozotocin to
induce diabetes, and monitoring the integrity of the graftally rapidly. Third, after transfer of the CD81 T cell clone
into NOD mice, expression of Fas was rapidly induced over time. They found that islet grafts from wild-type
mice or mutants lacking Fas, the a chain of the IFNgon b cells. These data provide strong evidence that Fas
is a major mediator of b cell death in this CD81 T cell receptor (R), or TNF-R2 were destroyed, while those
from mutants devoid of TNF-R1 survived. This wouldtransfer model of diabetes. It is not yet clear whether
Fas-mediated death plays an important role in the spon- seem to implicate a TNF/TNF-R1 interaction in the death
of b cells in this model, in line with the many reportstaneous NOD model. The significance of the reported
block in spontaneous diabetes in NOD lpr/lpr mice is implicating TNFa in the progression to diabetes in NOD
mice (see discussion in Sarvetnick, 1996).obscured by the known pleiotropic effects of the fas
gene mutationÐe.g., lymphoadenopathy, dysregulation So the picture we have at the moment is a cloudy
one: data from three different diabetes models implicat-of T cell populations, polyclonal B cell stimulation,
strong constitutive up-regulation of FasL on lympho- ing three distinct death effector systemsÐFas/FasL,
perforin, and TNF/TNF-R1Ðand not yet clearly indicat-cytes (Chu et al., 1995, and references therein). This
problem could have been circumvented at least partially ing which of them (or others) are most important in the
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Ohashi, P.S., Oehen, S., Buerki, K., Pircher, H., Ohashi, C.T., Oder-NOD model, not to mention diabetes in human patients.
matt, B., Malissen, B., Zinkernagel, R.M., and Hengartner, H. (1991).With regard to humans, it is important to keep in mind
Cell 65, 305±317.that patients can present with quite heterogeneous clini-
Pakala, S.V., Chivetta, M.L., and Katz, J.D. (1997). J. Allergy Clin.cal parameters (Bach, 1994), and thus diabetes in man
Immunol. 99, 6380.
could be a set of related disorders with possible differ-
Sarvetnick, N. (1996). J. Exp. Med. 184, 1597±1600.
ences in inciting antigen, primary effector cell type, and,
Spencer, D.M. (1996). Trends Genet. 12, 181±187.most relevant here, mechanism of b cell destruction. It
Tisch, R., and McDevitt, H. (1996). Cell 85, 291±297.is not known at present which of the mouse models
Vaux, D.L., and Strasser, A. (1996). Proc. Natl. Acad. Sci. USA 93,will prove the best for studying which of the human
2239±2244.
variations. Neither is it known whether islet grafts are
Wang, B., Gonzalez, A., Benoist, C., and Mathis, D. (1996). Eur. J.subject to the same or different mechanisms of destruc-
Immunol. 26, 1762±1769.
tion, an important question given the increasing interest
Wong, F.S., Visintin, I., Wen, L., Flavell, R.A., and Janeway, C.A.
in using islet xenografts to attenuate disease. (1996). J. Exp. Med. 183, 67±76.
Although this is clearly a complicated issue, and the
data reported so far suggest that its resolution will be
complex, it is an issue well worth tackling because of
the obvious therapeutic implications: the potential to
engineer death-defying b cells, an achievement which
could significantly advance islet graft technology. One
might attempt to block the different candidate death
effector molecules one by one, and in combination, in
the various mouse models. This could be achieved by
treatment with the appropriate blocking reagents
(MAbs, soluble receptors), by introducing the relevant
null gene mutations or dominant negative mutants in a
time-controlled fashion and specifically on islet b cells,
or only on the relevant attacking population of lympho-
cytes. (Wholesale knockout or transgenic approaches
to manipulate such molecules have pleiotropic effects,
and would be difficult to unravel.) The technology to
accomplish this is available, if heavy (reviewed in Spen-
cer, 1996). Even more rigor and ingenuity will need to
be applied to the human system. Although correlations
between enhanced expression of particular death ef-
fector molecules and autoimmune destruction (e.g.,
Dowling et al., 1996; Giordano et al., 1997) are tantaliz-
ing, they can not be taken as proof of causality. Here
too, other strategies have to be devisedÐfor example,
more effectively exploiting the potential of human-
ized severe combined immunodeficiency (SCID) mice
(MoÈ ller, 1991).
Given the importance of the task to be accomplished,
the difficulties raised above should not be viewed as
encumbrances, but as stimuli.
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